Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125788 · ClinicalTrials.gov registry record · Phase 2
L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
A Phase 2 study, sponsored by Emmaus Medical.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00125788: Completed Phase 2 study, sponsored by Emmaus Medical.
NCT00125788 is a Phase 2 study that has completed, run by Emmaus Medical. The registered enrollment target is 70 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00125788, a Phase 2 study, has completed, sponsored by Emmaus Medical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate the effects of L-glutamine as a therapy for sickle cell anemia and sickle ß0-thalassemia. as evaluated by the number of occurrences of sickle cell crises.
Primary Outcome
The mean number of painful sickle crisis through week 48
Interventions
- DRUG Placebo
- DRUG L-glutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2004-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00125788 record still lists
NCT00125788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00125788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00125788 about?
NCT00125788 is a clinical study titled "L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia". The purpose of this research is to evaluate the effects of L-glutamine as a therapy for sickle cell anemia and sickle ß0-thalassemia. as evaluated by the number of occurrences of sickle cell crises.
What is the current status of trial NCT00125788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2004-03. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00125788?
The interventions under investigation include: Placebo (DRUG), L-glutamine (DRUG).
Who is sponsoring clinical trial NCT00125788?
This trial is sponsored by Emmaus Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00125788's enrollment target sits among peer trials
70 937th of 2000 higher than 1,036 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia